We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Researchers Reveal a Microchip Magnetic Cell Sorting Device

By LabMedica International staff writers
Posted on 07 Mar 2016
A novel magnetic cell sorting system may potentially be reduced in size for development into a "lab-on-a-chip" device.

The system, which was invented by investigators at the University of California, Los Angeles (USA), comprised a microchip coated with an array of microscale pillars set progressively farther apart, and a spinning magnet that pulled magnetically labeled cells over the pillars. More...
The system separated and concentrated magnetic beads based on iron oxide content (IOC) and cells based on surface expression. Particles with higher IOC separated and equilibrated along the miropillar array at larger pitches.

The investigators described using the method in the February 17, 2016, online edition of the journal Small. They reported that LNCaP cells were separated based on the bound quantity of one-micrometer anti-epithelial cell adhesion molecule (EpCAM) particles as a metric for expression. The ratcheting cytometry system was able to resolve a differential of 13 bound particles, successfully distinguishing LNCaP from PC3 populations based on EpCAM expression. This result matched that obtained with fluorescence-based flow cytometry analysis. As a proof-of-concept, EpCAM-labeled cells from patient blood were isolated with 74% purity, demonstrating the device's potential as a quantitative magnetic separation instrument.

“What we think is only one cell type is often a heterogeneous mixture, and without technologies to separate quantitatively, these nuanced differences get lost,” said senior author Dr. Dino Di Carlo, professor of bioengineering at the University of California, Los Angeles. “For example, therapeutically active progenitor cells may look very similar to the other contaminating cells that provide no therapeutic benefit.”

Related Links:

University of California, Los Angeles



New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Immunofluorescence Analyzer
IFA System
New
Prefilled Tubes
Prefilled 5.0ml Tubes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.